Literature DB >> 17925498

Factors related to adherence to statin therapy.

Brandy McGinnis1, Kari L Olson, David Magid, Elizabeth Bayliss, Eli J Korner, David W Brand, John F Steiner.   

Abstract

BACKGROUND: Retrospective database analyses have revealed that 50% of patients receiving statins discontinue therapy after one year of treatment. Typically, these data do not focus on patient-specific reasons for discontinuation.
OBJECTIVE: To examine the reasons that patients discontinue statins and compare the patient and clinical factors of those who do and do not discontinue therapy.
METHODS: All patients with a new statin prescription between January 1, 2004, and March 31, 2004, were identified through pharmacy claims. Patients who had discontinued and continued statin therapy were identified. Medical records were reviewed to determine whether there were documented reasons for statin discontinuation. Subsequently, telephone surveys addressing statin knowledge, relationships, communication with healthcare providers, and general health status were conducted.
RESULTS: At one year, 47.5% (n = 671) of patients had obtained fewer than 80% of the refills of their prescribed statin. We reviewed 435 medical records and conducted 255 patient surveys. A total of 29.9% of discontinuers had reasons documented in the medical record. Compared with continuers, fewer discontinuers had follow-up and/or laboratory visits with a provider within 6 months after the start of statin therapy. The surveys indicated that more continuers than discontinuers trusted their providers (p < 0.05) and felt that providers had adequate knowledge to answer their questions (p < 0.001). In contrast, more discontinuers felt the statin was of limited benefit/unsure of the benefit (p < 0.001) and believed that their providers were not interested in their input on their medical condition (p < 0.01).
CONCLUSIONS: Utilizing pharmacy claims records alone to determine statin nonadherence may not only overestimate the percentage of patients who are nonadherent, but also prevent healthcare providers from understanding the reasons that patients discontinue or continue statin therapy. Statin adherence is complex and affected by several factors. Interventions to improve adherence should focus on patient communications, education, and follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925498     DOI: 10.1345/aph.1K209

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  44 in total

1.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

2.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

3.  Lipid therapy: A new whiteboard video for patient education.

Authors:  Margaret L Ackman; Sheri Koshman; Glen J Pearson; William Semchuk; Yana Shamiss; Ann Thompson; Travis Warner
Journal:  Can Pharm J (Ott)       Date:  2021-04-23

4.  The associations of clinicians' implicit attitudes about race with medical visit communication and patient ratings of interpersonal care.

Authors:  Lisa A Cooper; Debra L Roter; Kathryn A Carson; Mary Catherine Beach; Janice A Sabin; Anthony G Greenwald; Thomas S Inui
Journal:  Am J Public Health       Date:  2012-03-15       Impact factor: 9.308

5.  Family history of cardiovascular disease and influence on statin therapy persistence.

Authors:  Anna Citarella; Helle Kieler; Anders Sundström; Marie Linder; Björn Wettermark; Ingegärd Anveden Berglind; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2014-03-08       Impact factor: 2.953

Review 6.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

7.  Defining an evidence-based cutpoint for medication adherence in heart failure.

Authors:  Jia-Rong Wu; Debra K Moser; Marla J De Jong; Mary Kay Rayens; Misook L Chung; Barbara Riegel; Terry A Lennie
Journal:  Am Heart J       Date:  2008-12-24       Impact factor: 4.749

8.  Exploring patients' reasons for discontinuance of heart medications.

Authors:  Linda Garavalia; Brian Garavalia; John A Spertus; Carole Decker
Journal:  J Cardiovasc Nurs       Date:  2009 Sep-Oct       Impact factor: 2.083

9.  Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases.

Authors:  Marsha A Raebel; Julie Schmittdiel; Andrew J Karter; Jennifer L Konieczny; John F Steiner
Journal:  Med Care       Date:  2013-08       Impact factor: 2.983

Review 10.  Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

Authors:  S Matthijs Boekholdt; G Kees Hovingh; Samia Mora; Benoit J Arsenault; Pierre Amarenco; Terje R Pedersen; John C LaRosa; David D Waters; David A DeMicco; R John Simes; Antony C Keech; David Colquhoun; Graham A Hitman; D John Betteridge; Michael B Clearfield; John R Downs; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; Scott M Grundy; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2014-08-05       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.